Fesoterodine ameliorates the activity in frontal brain micturition area and the hypersensibility of bladder afferent nerves in patients with OAB symptoms.

Trial Profile

Fesoterodine ameliorates the activity in frontal brain micturition area and the hypersensibility of bladder afferent nerves in patients with OAB symptoms.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2014

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top